title: Re-evaluating the New Committee on Infectious Diseases Recommendations for Palivizumab Use in Premature Infants.
authors.affiliation: From the *Northwestern University Feinberg School of Medicine, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois; †State University of New York Stony Brook School of Medicine, Winthrop University Hospital, New York, New York; ‡Texas A & M University, Driscoll Children's Hospital, Corpus Christi, Texas; and §State University of New York, Upstate Medical University, Upstate Golisano Children's Hospital, Syracuse, New York.
authors.forename: Ram
authors.initials: R
authors.lastname: Yogev
authors.forename: Leonard R
authors.initials: LR
authors.lastname: Krilov
authors.forename: Jaime E
authors.initials: JE
authors.lastname: Fergie
authors.forename: Leonard B
authors.initials: LB
authors.lastname: Weiner
mesh_terms: D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D007223:Infant; D007231:Infant, Newborn; D007234:Infant, Premature; D000069455:Palivizumab / Q000627:therapeutic use*; D017410:Practice Guidelines as Topic; D018357:Respiratory Syncytial Virus Infections / Q000188:drug therapy* / Q000517:prevention & control*
chemical_list: D007155:Immunologic Factors; D000069455:Palivizumab